The convergence of wearable biometric sensors, continuous physiological monitoring, and advanced natural language processing has catalysed a fundamental shift in personal health management. A rapidly growing cohort of quantified-self practitioners, popularly termed "datamaxxers", is transforming personal wellness by systematically ingesting granular biometrics, clinical records, and behavioural logs into conversational artificial intelligence platforms. Rather than relying on

On August 11th, 2026, Flagler Health announced the completion of a $50 Million Series B financing round, bringing its total capital raised to $63 Million. The investment was led by Bessemer Venture Partners, with participation from a syndicate of institutional venture investors including SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures and Offscript. Legal counsel for the financing transaction was executed by Wilson Sonsini Goodrich & Rosati,

The global artificial intelligence landscape is witnessing a structural shift as top-tier foundation model developers transition from private capital funding cycles to public equity markets. At the centre of this transition is Anthropic, which confidentially submitted a Form S-1 draft registration statement to the U.S. Securities and Exchange Commission (SEC) on June 1st, 2026. Coming on the heels of a $65 Billion Series H funding round that valued the enterprise at $965 Bill

Between co-founding Zesty in 2012 and building it into one of the UK's leading patient portals, negotiating a Value Added Reseller agreement with Cerner that took three years to close and multiplied our annual revenue significantly, and raising capital from US, European & UK Venture Capital Funds across five very different vintages, I accumulated scar tissue that I now put to work advising founders, investors and boards at Nelson Advisors.

The European Union has embarked on an ambitious regulatory effort to establish digital and data sovereignty across critical economic sectors. At the centre of this strategy lies the European Health Data Space (EHDS) Regulation (EU) 2025/327 which officially entered into force on March 26th, 2025. By creating a single market for electronic health data, the European Commission seeks to empower citizens, streamline cross-border clinical care and unleash secondary health data re

Over the 2024–2027 planning horizon, Samsung Electronics and its healthcare subsidiaries, including Samsung Medison and Samsung HME America are executing a coordinated transition from traditional medical hardware manufacturing toward a vertically integrated, data driven healthcare ecosystem. This strategic evolution centres on bridging two historically separated sectors: enterprise hospital diagnostic equipment and continuous consumer biometric monitoring.

Healthcare enterprises operate in an environment where legacy Electronic Health Record (EHR) platforms, such as Epic, Oracle Cerner, Allscripts and NextGen, serve as the foundational bedrock of clinical operations. These systems were engineered specifically for clinical charting, regulatory documentation, diagnostic order entry and transactional billing. However, legacy EHR platforms were not designed to deliver dynamic, personalised patient engagement, modern omni channel co

On August 5th, 2026, iRhythm Holdings, Inc. (NASDAQ: IRTC) executed a definitive merger agreement to acquire privately held Vital Connect, Inc. for an aggregate transaction value of approximately $287.5 million. The transaction consideration comprises $237.5 million in cash, funded directly from iRhythm's existing balance sheet, alongside $50.0 million in iRhythm common stock. To maintain operational continuity and support VitalConnect’s working capital requirements through t

Every conference panel on European digital health ends in the same place. The moderator asks what is holding the sector back and the answer arrives on cue: capital. Europe needs deeper venture pools, more growth equity, a European Nasdaq, pension reform, sovereign scale-up funds. If only the money were there, the argument runs, Europe's HealthTech companies would scale into global champions instead of selling early or fading quietly away.

The biopharmaceutical and digital health sectors are undergoing a structural convergence driven by asymmetric financial pressures, shifting commercial models, and evolving regulatory frameworks. Biopharma is entering an aggressive loss of exclusivity (LOE) cycle, frequently designated the "super patent cliff," in which an estimated $200 Billion to $300 Billion in annual global branded revenues will expire between 2025 and 2030. This impending revenue contraction coincides wit

Market commentator Jim Cramer outlined an earnings based framework organising current market dynamics into five dominant themes: resilient discretionary consumer demand, artificial intelligence wafer fabrication equipment, consolidated enterprise cybersecurity platforms, a structural rebound in mergers and acquisitions, and healthcare innovation as a defensive growth ballast.

Telehealth has completed its transition from a speculative, venture-backed growth category to permanent healthcare infrastructure. Following the unprecedented surge during the early stages of the COVID-19 pandemic, when virtual care claims spiked to 78 times pre-pandemic levels, utilization has settled into a durable equilibrium approximately 38 times higher than pre-2020 baselines. Outpatient and office visit virtualisation has stabilised between 13% and 17% across clinical

The global healthcare landscape is experiencing a re-evaluation of women’s health technology (commonly termed "femtech"). Historically treated as a niche sector concentrated around direct-to-consumer (DTC) reproductive apps and fertility solutions, women’s health tech has expanded into a complex, multi-specialty asset class spanning biopharma, AI-driven diagnostics, maternal care, midlife health, and chronic disease management.

The global paradigm shift toward generative artificial intelligence and foundation models has transformed healthcare research, diagnostic radiology, digital pathology and drug discovery. However, this technological frontier has intensified a critical strategic vulnerability for Europe: a profound structural reliance on United States technology conglomerates for computational hardware, cloud infrastructure, and frontier foundation models. While American technology leaders depl

The European healthcare technology (HealthTech) and medical technology (MedTech) landscape has entered an era of industrial maturity. Following a post-pandemic recalibration, market dynamics reflect a structural shift characterised as "The Great Rationalisation," wherein speculative top-line expansion has been replaced by strict underwriting standards centered on clinical pathway integration, regulatory fortification, margin sustainability, and demonstrated return on investme